Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or flupentixol and, on the other hand, a newer antipsychotic compound like olanzapine, quetiapine or aripiprazole in patients with schizophrenia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Bremen
• Collaborator: German Federal Ministry of Education and Research
• Treatments: Antipsychotic Agents; Aripiprazole; Flupenthixol; Flupenthixol decanoate; Haloperidol; Haloperidol decanoate; Olanzapine; Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Schizophrenia

• age 18-65 years

• necessity to establish new or change antipsychotic treatment due to unsatisfying results or side effects

• written informed consent

Exclusion Criteria (amongst others):

• Known or suspected hypersensitivity to olanzapine, quetiapine, aripiprazole, flupentixol or haloperidol

• Acute suicidal tendency

• "Einwilligungsvorbehalt (BGB)" or "Unterbringung (PsychKG)"

• Epilepsy

• Organic psychosis

• Parkinson Disease

• Dementia

• History of malignant neuroleptic syndrome

• QTc interval ≥ 0.5s / history of congenital QTc prolongation